Molecular Diagnostics News and Research

RSS

Data presented at AACR 2015 recognizes value of EKF PointMan technology for assessing lung cancer mutation status

The PointMan EGFR DNA enrichment kit, a novel method for selective amplification of genotype specific sequences.

From EKF Diagnostics 21 Apr 2015

Focus Diagnostics announces FDA clearance for Simplexa Group A Strep Direct Kit

Focus Diagnostics, the clinical-laboratory products business of Quest Diagnostics, today announced the FDA 510(k) clearance and CLIA moderate-complexity categorization for its Simplexa Group A Strep Direct Kit. Simplexa Group A Strep Direct is a real-time polymerase chain reaction assay for the detection of Group A Streptococcus bacteria directly from throat swabs.

From Quest Diagnostics 15 Apr 2015

Atlas Genetics signs diagnostic collaboration to explore new use of io system

Atlas Genetics Ltd, the ultra-rapid 'test and treat' molecular diagnostics company, today announces that it has entered into a collaboration with a major pharmaceutical company to develop a diagnostic test, expanding capabilities beyond infectious diseases.

15 Apr 2015

New data support use of Exalenz Bioscience's BreathID test for diagnosing H. pylori infection

Exalenz Bioscience, a leader in developing and marketing non-invasive medical devices for diagnosing and monitoring a range of gastrointestinal and liver diseases, today announced new published data supporting the use of the Company's point-of-care BreathID urea breath test for diagnosing Helicobacter pylori infection (H. pylori) in the emergency department (ED) setting.

13 Apr 2015

MammaPrint 70-gene breast cancer recurrence assay recommended in Germany’s AGO Guidelines

Agendia, a leading molecular diagnostics company that develops and markets genomic diagnostic products, announced at the St. Gallen International Breast Cancer Conference that new guidelines of the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) recommend the MammaPrint® 70-gene breast cancer recurrence assay in Germany’s 2015 guidelines for early-stage invasive breast cancer.

9 Apr 2015

Mobidiag announces CE-IVD marking and launching of Amplidiag C. difficile+027 test

Mobidiag Ltd, a Finnish molecular diagnostics company specialized in the development of innovative diagnostics solutions for infectious diseases, today announced the launch of Amplidiag C. difficile+027, a qualitative qPCR-based test performed from DNA extracted from stool in suspected cases of C. difficile infection (CDI).

9 Apr 2015

Frost & Sullivan forecasts growth of global healthcare market

The healthcare industry is entangled in a transitory phase in which therapeutics, devices, products and services are sold into traditional care settings that are unable to keep up with the requirements placed upon it by changing demographics and consumer needs. At the same time, opportunities for new services and care, such as ambulatory, mobile, and home care, lack the appropriate level of maturity to provide robust revenue streams despite having the promise to increase healthcare delivery efficiency and reduce long term costs.

8 Apr 2015

Cepheid's Xpert Ebola diagnostic test granted FDA Emergency Use Authorization

Cepheid today announced it has received Emergency Use Authorization from the U.S. Food & Drug Administration for Xpert Ebola, a molecular diagnostic test for Ebola Zaire Virus that delivers results in less than two hours.

25 Mar 2015

Sigma-Aldrich, Roche sign distribution agreement for Biochemical Reagents products

Sigma-AldrichCorporation, a leading Life Science and Technology company, announced today it signed an exclusive global distribution agreement with Roche. The agreement pairs Roche's high-quality Biochemical Reagents product portfolio with the industry-leading eCommerce and supply chain capabilities of Sigma-Aldrich.

19 Mar 2015

Fast and focused sequencing from single genes to entire exomes

Integrated DNA Technologies (IDT) will host a talk on maximizing efficiency of NGS enrichment panels at the qPCR & NGS 2015 Advanced Molecular Diagnostics for Biomarker Discovery Symposium on Monday March 23rd at 3PM. The talk will detail current technical issues faced by researchers when using hybridization enrichment panels and provide practical advice on how to increase successes while reducing time and costs in targeted sequencing.

From Integrated DNA Technologies 16 Mar 2015

NMR screening solution specifically for the analysis of honey launched by Bruker

This new NMR screening solution specifically for the analysis of honey is the most recent module of Bruker’s well-established FoodScreener™ product line to be released in April.

From Bruker 10 Mar 2015

Wine-Profiling solution based on NMR introduced by Bruker

This substantially enhanced second-generation module of the FoodScreener™ for wine profiling allows easy and cost-efficient NMR-based wine analysis, now for the first time also for key regions in France, Italy and Spain. In addition to geographical origin, NMR Wine Profiling can determine further key authenticity parameters such as grape variety, vintage year and possible water addition. This comprehensive solution offers a quick, fully automated and cost-efficient tool to ensure wine quality and authenticity, protecting brand integrity and consumer confidence.

From Bruker 10 Mar 2015

Myriad Publishes myPath™ Melanoma Pivotal Validation Study in the Journal of Cutaneous Pathology

Myriad Genetics, Inc. (NASDAQ: MYGN) today announced the Journal of Cutaneous Pathology published data from a pivotal clinical validation study that showed the myPath™ Melanoma test is highly effective at differentiating benign skin moles from malignant melanoma with greater than 90 percent diagnostic accuracy. Melanoma is the most dangerous type of skin cancer and more than 76,000 new cases of melanoma are diagnosed each year in the United States.

6 Mar 2015

MRIGlobal awarded contract to develop Sample-to-Sequence system for diagnosis of infectious diseases

MRIGlobal today announced that it has been awarded a $14.8 million contract to develop an end-to-end next generation sequencing system for clinical diagnosis of infectious diseases.

23 Feb 2015

Biocartis to develop Rapid Ebola Virus Triage Test

Biocartis believes its Rapid Ebola Virus Triage Test could provide a sustainable solution for rapid detection of Ebola-infected patients even after the current Ebola outbreak.

From Biocartis 10 Feb 2015

Trovagene to sell underwritten public offering of common stock

Trovagene, Inc., a developer of cell-free molecular diagnostics, today announced that it is offering to sell shares of its common stock in an underwritten public offering. The offering is expected to price on or about Friday, February 6, 2015.

6 Feb 2015

EKF Molecular Diagnostics collaborates with ANGLE for liquid biopsy development using Parsortix and PointMan technologies

EKF Molecular Diagnostics has agreed a collaboration with specialist medtech company ANGLE plc, to investigate the combination of ANGLE's Parsortix circulating tumour cell (CTC) harvesting platform with EKF Molecular's PointMan™ DNA enrichment technology as a liquid biopsy. If successful, the resulting simple blood test could enable the investigation of unexpected ultra-low level mutations in a patient's cancer for personalised cancer care.

29 Jan 2015

Cypher Genomics, Sequenom sign development agreement for noninvasive prenatal tests

Cypher Genomics, Inc., the leading genome informatics company, and Sequenom, Inc., the leading molecular diagnostics company, today announced a development agreement for next generation noninvasive prenatal tests (NIPT).

22 Jan 2015

EKF highlighting heat and humidity compatible POC hemoglobin analyzer at Arab Health 2015

EKF Diagnostics, the global diagnostics company, announces that it will be highlighting the robustness of its new DiaSpect Tm POC hemoglobin analyzer.

From EKF Diagnostics 15 Jan 2015

$Aptose begins APTO-253 clinical study in patients with relapsed or refractory hematologic malignancies$

Aptose begins APTO-253 clinical study in patients with relapsed or refractory hematologic malignancies

Aptose Biosciences Inc., a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, today announced dosing of the first patient in its Phase 1b clinical study of APTO-253 in patients with relapsed or refractory hematologic malignancies.

13 Jan 2015